ZX-7101A + oseltamivir

ZX-7101A + oseltamivir is a fixed-dose combination therapy for influenza treatment, bringing together two distinct antiviral agents: **ZX-7101A**, a novel oral small molecule **cap-dependent endonuclease (polymerase acidic protein, PA protein) inhibitor**, and **oseltamivir**, an established systemic oral **neuraminidase inhibitor**[1][3][5][6]. ZX-7101A, a prodrug, is rapidly converted in vivo to the active ZX-7101, interfering with influenza viral RNA transcription and thus inhibiting viral replication[1][3][5]. Oseltamivir acts by inhibiting influenza virus neuraminidase, blocking viral release from infected cells and further spread[2][6]. Both agents target influenza A and B, including certain avian strains, and combination therapy aims to maximize viral suppression and reduce resistance. ZX-7101A is developed for single-dose oral treatment, while oseltamivir is dosed orally for acute or prophylactic influenza therapy. The main indication for the combination is the **treatment of uncomplicated influenza (A and B)** in adults. ZX-7101A is under clinical investigation, and oseltamivir (Tamiflu) is approved for use globally[1][2][3][4][6].

Brand names

Tamiflu

Other names

cap-dependent endonuclease inhibitor + neuraminidase inhibitor